Quality-of-life-adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma: An aid to clinical decision making

Journal of Clinical Oncology

Volumn 16, Issue 7, 1998, Pages 2339-2344

  Cole, Bernard F ^a   Solal Céligny, Philippe ^b   Gelber, Richard D ^b   Lepage, Eric ^b   Gisselbrecht, Christian ^b   Reyes, Félix ^b   Sebban, Catherine ^b   Sugano, David ^b   Tendler, Craig ^b   Goldhirsch, Aron ^b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; TENIPOSIDE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DECISION MAKING; DISEASE COURSE; DRUG MONITORING; DRUG SCREENING; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; TREATMENT OUTCOME;

EID: 0345676551     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.7.2339     Document Type: Article

References (16)

1. Solal-Céligny P, Lepage E, Brousse N, et al: Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. N Engl J Med 329:1608-1614, 1993
2. Solal-Céligny P, Brousse N, LePageE, et al: A doxorubicin-containing regimen with or without interferon alpha 2b in advanced follicular lymphomas: Final analysis of survival and toxicity of the GELF 86 trial. J Clin Oncol 16:2332-2338, 1998
3. Gelber RD, Goldhirsch A: A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. J Clin Oncol 4:1772-1779, 1986
4. Goldhirsch A, Gelber RD, Simes RJ, et al: Costs and benefits of adjuvant therapy in breast cancer: A quality adjusted survival analysis. J Clin Oncol 7:36-44, 1989
5. Glasziou PP, Simes RJ, Gelber RD: Quality adjusted survival analysis. Stat Med 9:1259-1276, 1990
6. Gelber RD, Cole BF, Gelber S, et al: Comparing treatments using quality-adjusted survival: The Q-TWiST method. Am Stat 49:161-169, 1995
7. Gelber RD, Goldhirsch A, Cavalli F: Quality-of-life-adjusted evaluation of a randomized trial comparing adjuvant therapies for operable breast cancer. Ann Intern Med 114:621-628, 1991
8. Gelber RD, Goldhirsch A, Hürny C, et al: Quality of life in clinical trials of adjuvant therapies. JNCI Monogr 11:127-135, 1992
9. Cole BF, Gelber RD, Goldhirsch A: A quality adjusted survival meta-analysis of adjuvant chemotherapy for premenopausal breast cancer. Stat Med 14:1771-1784, 1995
10. Gelber RD, Cole BF, Goldhirsch A, et al: Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: A meta-analysis using quality-adjusted survival. Lancet 347:1066-1071, 1996
11. Gelber RD, Lenderking WR, Cotton DJ, et al: Quality-of-life evaluation in a clinical trial of zidovudine therapy in patients with mildly symptomatic HIV infection. Ann Intern Med 116:961-966, 1992
12. Lenderking WR, Gelber RD, Cotton DJ, et al: Evaluation of the quality-of-life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. N Engl J Med 330:738-743, 1994
13. Gelber RD, Goldhirsch A, Cole BF, et al: A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer. J Natl Cancer Inst 88:1039-1045, 1996
14. Cole BF, Gelber RD, Kirkwood JM, et al: A quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment for high-risk resected cutaneous melanoma: An Eastern Cooperative Oncology Group study (E1684). J Clin Oncol 14:2666-2673, 1996
15. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 54:457-481, 1958
16. Cole BF: Evaluating the clinical and economic trade-offs of hepatic arterial infusion. J Nat Cancer Inst 88:223-224, 1996 (editorial)